Global Necrotizing Entrecolitis Market is Anticipated to Show Growth by 2025

2018-05-21 14:51:45

According to a new report published by Reports Monitor titled, “Global Necrotizing Enterocolitis  Market” the global Necrotizing Enterocolitis market was valued at XX million in 2018, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2018 to 2025. 

Necrotizing Enterocolitis or NEC is a devastating disease which affects usually the intestine of premature infants. In this disease, the wall of the intestine is attacked by bacteria, which can cause local infection and inflammation that can eventually destroy the wall of the intestine. The intestine or bowel wall damage can lead to opening of the intestine walls causing spillage of stool into the infant’s abdomen, this can result in a serious infection and death. The premature infants are generally the most vulnerable of this devastating disease. 

The improved reimbursement policies and framework in developed countries, unmet medical needs,  growing research funding, and increasing government assistance are continuously have immensely contributed to the growth of the global market. However, there are some issues associated with the necrotising enterocolitis market. The complications in the treatment of this disease, lack of skilled or trained physicians and doctors, and poor healthcare infrastructure in low and middle-income economies may hamper the growth of the global necrotizing entercolitis market. The government’s constant efforts to improve the healthcare infrastructure by making huge investments in healthcare sector can further enhance the market growth in the developing nations worldwide.

The global necrotizing entercolitis market is segmented on the basis of stage which includes three stages, Stage I, Stage II, and Stage III. Stage II is furthermore bifurcated into Stage IIa and Stage IIb. The Stage III is further classified into Stage IIIa and Stage IIIb.

Moreover, the market is segmented on the basis of diagnosis such as imaging, laboratory studies, and differential diagnosis. Furthermore, on the basis of end- user market is segregated as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others.

Furthermore, on the basis of treatment, the global necrotizing entercolitis market is classified as Total Parenteral Nutrition or TPN, gastrointestinal decompression, antifungal treatment, paracentesis, antimicrobial therapy, and Others.

The global necrotizing entercolitis market is dominated by America owing well developed technology, high healthcare spending and presence of leading players. According to the report of Centers for Disease Control and Prevention in 2015, total health expenditure in the U.S. region moreover, presence of geriatric population and government support have fuelled the market growth in America. Europe accounts for the second leading market which is followed by Asia Pacific. Strong government support and favorable research policies have driven the growth of Europe market. Asia Pacific is the fastest growing market due to huge untapped opportunity for the development of the market. Rising government spending and increasing premature infant births in APAC can trigger the market in near future in countries like India, China, 

On the other hand, the Middle East & Africa holds the least share in the market due to presence of poor economies in Africa region.

The major key players in this market are Abbott Laboratories Inc., Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Company Ltd., Eli Lilly and Co., Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, GI Supply, GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Medtronic Plc, Merck & Co. Inc., MiddleBrook Pharmaceuticals, Novartis AG, Pfizer Inc., Sanofi-Aventis (France), Sequana Medical AG, and Takeda Pharmaceutical Company Ltd.

About Us:

We at Garner provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.

Contact Us:

Mr. Kevin Thomas


+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]

Related Press Releases